- Home
- ROIV vs BFAM Comparison
ROIV vs BFAM Comparison
Compare ROIV & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- BFAM
- Stock Information
- Founded
- ROIV 2014
- BFAM 1986
- Country
- ROIV United Kingdom
- BFAM United States
- Employees
- ROIV N/A
- BFAM N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- BFAM Other Consumer Services
- Sector
- ROIV Health Care
- BFAM Consumer Discretionary
- Exchange
- ROIV Nasdaq
- BFAM Nasdaq
- Market Cap
- ROIV 8.4B
- BFAM 6.9B
- IPO Year
- ROIV N/A
- BFAM 1997
- Fundamental
- Price
- ROIV $10.79
- BFAM $124.33
- Analyst Decision
- ROIV Buy
- BFAM Buy
- Analyst Count
- ROIV 4
- BFAM 8
- Target Price
- ROIV $17.50
- BFAM $139.13
- AVG Volume (30 Days)
- ROIV 5.9M
- BFAM 420.9K
- Earning Date
- ROIV 05-29-2025
- BFAM 05-05-2025
- Dividend Yield
- ROIV N/A
- BFAM N/A
- EPS Growth
- ROIV N/A
- BFAM 93.82
- EPS
- ROIV N/A
- BFAM 2.77
- Revenue
- ROIV $122,585,000.00
- BFAM $2,728,831,000.00
- Revenue This Year
- ROIV N/A
- BFAM $9.60
- Revenue Next Year
- ROIV N/A
- BFAM $7.51
- P/E Ratio
- ROIV N/A
- BFAM $44.96
- Revenue Growth
- ROIV 140.04
- BFAM 9.71
- 52 Week Low
- ROIV $8.73
- BFAM $100.59
- 52 Week High
- ROIV $13.06
- BFAM $141.90
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- BFAM 54.57
- Support Level
- ROIV $10.58
- BFAM $118.89
- Resistance Level
- ROIV $11.77
- BFAM $125.25
- Average True Range (ATR)
- ROIV 0.34
- BFAM 3.36
- MACD
- ROIV -0.07
- BFAM 0.05
- Stochastic Oscillator
- ROIV 17.65
- BFAM 55.91
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About BFAM Bright Horizons Family Solutions Inc.
Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.